ImmuPharma (LON:IMM) Shares Up 30.2% – Here’s What Happened

Shares of ImmuPharma plc (LON:IMM) shot up 30.2% on Monday . The stock traded as high as GBX 19.35 ($0.26) and last traded at GBX 18.20 ($0.25). 38,553,926 shares traded hands during mid-day trading, an increase of 365% from the average session volume of 8,294,800 shares. The stock had previously closed at GBX 13.98 ($0.19).

ImmuPharma Trading Up 30.2%

The company has a market capitalization of £90.95 million, a price-to-earnings ratio of -2,044.94 and a beta of 1.53. The firm has a 50-day simple moving average of GBX 3.12 and a two-hundred day simple moving average of GBX 2.91.

ImmuPharma (LON:IMM) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.